Claire Paquet

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3483988/publications.pdf

Version: 2024-02-01

118	3,190	186265	182427
papers	citations	28 h-index	51 g-index

134	134	134	3954
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Association of sleep duration in middle and old age with incidence of dementia. Nature Communications, 2021, 12, 2289.	12.8	254
2	Consensus guidelines for lumbar puncture in patients with neurological diseases. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2017, 8, 111-126.	2.4	197
3	Performance and complications of lumbar puncture in memory clinics: Results of the multicenter lumbar puncture feasibility study. Alzheimer's and Dementia, 2016, 12, 154-163.	0.8	179
4	Oxidative stress increases BACE1 protein levels through activation of the PKR-eIF2Î± pathway. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2012, 1822, 885-896.	3.8	139
5	Long COVID: cognitive complaints (brain fog) and dysfunction of the cingulate cortex. Journal of Neurology, 2022, 269, 44-46.	3.6	127
6	The pre-synaptic vesicle protein synaptotagmin is a novel biomarker for Alzheimerâ€™s disease. Alzheimer's Research and Therapy, 2016, 8, 41.	6.2	121
7	Cerebrospinal fluid amyloid-Î² 42/40 ratio in clinical setting of memory centers: a multicentric study. Alzheimer's Research and Therapy, 2015, 7, 30.	6.2	101
8	Seizures in dominantly inherited Alzheimer disease. Neurology, 2016, 87, 912-919.	1.1	81
9	Headâ€toâ€head comparison of clinical performance of CSF phosphoâ€tau T181 and T217 biomarkers for Alzheimer's disease diagnosis. Alzheimer's and Dementia, 2021, 17, 755-767.	0.8	81
10	Screening of dementia genes by whole-exome sequencing in early-onset Alzheimer disease: input and lessons. European Journal of Human Genetics, 2016, 24, 710-716.	2.8	77
11	Increased levels of cerebrospinal fluid JNK3 associated with amyloid pathology: links to cognitive decline. Journal of Psychiatry and Neuroscience, 2015, 40, 151-161.	2.4	75
12	Neuroinflammation and AÎ² Accumulation Linked To Systemic Inflammation Are Decreased By Genetic PKR Down-Regulation. Scientific Reports, 2015, 5, 8489.	3.3	70
13	Intersite variability of CSF Alzheimer's disease biomarkers in clinical setting. Alzheimer's and Dementia, 2013, 9, 406-413.	0.8	63
14	Neprilysin, cardiovascular, and Alzheimer's diseases: the therapeutic split?. European Heart Journal, 2015, 36, 902-905.	2.2	61
15	Relevance of AÎ²42/40 Ratio for Detection of Alzheimer Disease Pathology in Clinical Routine: The PLMR Scale. Frontiers in Aging Neuroscience, 2018, 10, 138.	3.4	59
16	Impact of harmonization of collection tubes on Alzheimer's disease diagnosis. , 2014, 10, S390-S394.e2.		58
17	Impact of cerebro-spinal fluid biomarkers of Alzheimerâ€™s disease in clinical practice: a multicentric study. Journal of Neurology, 2014, 261, 144-151.	3.6	56
18	Modulation of Tau Phosphorylation by the Kinase PKR: Implications in Alzheimer's Disease. Brain Pathology, 2011, 21, 189-200.	4.1	55

#	Article	IF	Citations
19	Increased Cerebrospinal Fluid Levels of Double-Stranded RNA-Dependant Protein Kinase in Alzheimer's Disease. Biological Psychiatry, 2012, 71, 829-835.	1.3	52
20	PKR involvement in Alzheimerâ€™s disease. Alzheimer's Research and Therapy, 2017, 9, 83.	6.2	52
21	Impact of the 2008â€“2012 French Alzheimer Plan on the Use of Cerebrospinal Fluid Biomarkers in Research Memory Center: The PLM Study. Journal of Alzheimer's Disease, 2013, 34, 297-305.	2.6	51
22	Dissection of synaptic pathways through the CSF biomarkers for predicting Alzheimer disease. Neurology, 2020, 95, e953-e961.	1.1	50
23	Cerebrospinal Fluid PKR Level Predicts Cognitive Decline in Alzheimerâ€™s Disease. PLoS ONE, 2013, 8, e53587.	2.5	46
24	A diagnostic scale for Alzheimerâ€™s disease based on cerebrospinal fluid biomarker profiles. Alzheimer's Research and Therapy, 2014, 6, 38.	6.2	44
25	The PKR Activator PACT Is Induced by AÎ²: Involvement in Alzheimer's Disease. Brain Pathology, 2012, 22, 219-229.	4.1	40
26	Age and the association between apolipoprotein E genotype and Alzheimer disease: A cerebrospinal fluid biomarkerâ€“based caseâ€“control study. PLoS Medicine, 2020, 17, e1003289.	8.4	39
27	STAT3 inhibition protects against neuroinflammation and BACE1 upregulation induced by systemic inflammation. Immunology Letters, 2020, 228, 129-134.	2.5	38
28	Association of Plasma p-tau181 and p-tau231 Concentrations With Cognitive Decline in Patients With Probable Dementia With Lewy Bodies. JAMA Neurology, 2022, 79, 32.	9.0	38
29	PKR downregulation prevents neurodegeneration and Î²-amyloid production in a thiamine-deficient model. Cell Death and Disease, 2015, 6, e1594-e1594.	6.3	32
30	Effect of active AÎ² immunotherapy on neurons in human Alzheimer's disease. Journal of Pathology, 2015, 235, 721-730.	4.5	31
31	Neuronal Phosphorylated RNA-Dependent Protein Kinase in Creutzfeldt-Jakob Disease. Journal of Neuropathology and Experimental Neurology, 2009, 68, 190-198.	1.7	29
32	Cognitive function after several years of antiretroviral therapy with stable central nervous system penetration score. HIV Medicine, 2013, 14, 311-315.	2.2	29
33	Cognitive decline and brainstem hypometabolism in long COVID: A case series. Brain and Behavior, 2022, 12, e32513.	2.2	29
34	Primary Progressive Aphasia in the Network of French Alzheimer Plan Memory Centers. Journal of Alzheimer's Disease, 2016, 54, 1459-1471.	2.6	28
35	PKR knockout in the 5xFAD model of Alzheimer's disease reveals beneficial effects on spatial memory and brain lesions. Aging Cell, 2019, 18, e12887.	6.7	28
36	Clinical reporting following the quantification of cerebrospinal fluid biomarkers in Alzheimer's disease: An international overview. Alzheimer's and Dementia, 2022, 18, 1868-1879.	0.8	26

#	Article	IF	Citations
37	A Novel ELISA for the Measurement of Cerebrospinal Fluid SNAP-25 in Patients with Alzheimerâ€™s Disease. Neuroscience, 2019, 420, 136-144.	2.3	25
38	Downregulated apoptosis and autophagy after antiâ€Aî² immunotherapy in Alzheimer's disease. Brain Pathology, 2018, 28, 603-610.	4.1	24
39	Who Needs Cerebrospinal Biomarkers? A National Survey in Clinical Practice. Journal of Alzheimer's Disease, 2014, 40, 857-861.	2.6	22
40	Differential Diagnosis of Dementia with High Levels of Cerebrospinal Fluid Tau Protein. Journal of Alzheimer's Disease, 2016, 51, 905-913.	2.6	21
41	Could PKR inhibition modulate human neurodegeneration?. Expert Review of Neurotherapeutics, 2009, 9, 1455-1457.	2.8	20
42	CSF levels of the BACE1 substrate NRG1 correlate with cognition in Alzheimerâ€™s disease. Alzheimer's Research and Therapy, 2020, 12, 88.	6.2	20
43	N-terminal and mid-region tau fragments as fluid biomarkers in neurological diseases. Brain, 2022, 145, 2834-2848.	7.6	20
44	Emotional memory enhancement in respect of positive visual stimuli in Alzheimer's disease emerges after rich and deep encoding. Cortex, 2015, 65, 89-101.	2.4	19
45	CSF level of Î²-amyloid peptide predicts mortality in Alzheimerâ€™s disease. Alzheimer's Research and Therapy, 2019, 11, 29.	6.2	19
46	Utility of CSF biomarkers in psychiatric disorders: a national multicentre prospective study. Alzheimer's Research and Therapy, 2016, 8, 27.	6.2	18
47	Biomarker profiles of Alzheimerâ€™s disease and dynamic of the association between cerebrospinal fluid levels of Î²-amyloid peptide and tau. PLoS ONE, 2019, 14, e0217026.	2.5	18
48	Effect of amyloidâ€Î² (<scp>A</scp>Î²) immunization on hyperphosphorylated tau: a potential role for glycogen synthase kinase <scp>(GSK</scp>)â€3Î². Neuropathology and Applied Neurobiology, 2015, 41, 445-457.	3.2	17
49	What is the clinical impact of cerebrospinal fluid biomarkers on final diagnosis and management in patients with mild cognitive impairment in clinical practice? Results from a nation-wide prospective survey in France. BMJ Open, 2019, 9, e026380.	1.9	17
50	The PKR/P38/RIPK1 Signaling Pathway as a Therapeutic Target in Alzheimerâ€™s Disease. International Journal of Molecular Sciences, 2021, 22, 3136.	4.1	17
51	Efficacy and Safety of Ketone Supplementation or Ketogenic Diets for Alzheimer's Disease: A Mini Review. Frontiers in Nutrition, 2021, 8, 807970.	3.7	17
52	Hyperuricemia, Gout, and the Brainâ€”an Update. Current Rheumatology Reports, 2021, 23, 82.	4.7	17
53	How many patients are eligible for disease-modifying treatment in Alzheimerâ€™s disease? A French national observational study over 5 years. BMJ Open, 2019, 9, e029663.	1.9	16
54	Clinical application of CSF biomarkers for Alzheimer's disease: From rationale to ratios. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2022, 14, e12314.	2.4	15

#	Article	IF	Citations
55	A cortical form of CADASIL with cerebral AÎ² amyloidosis. Acta Neuropathologica, 2010, 120, 813-820.	7.7	14
56	Exacerbated CSF abnormalities in younger patients with Alzheimer's disease. Neurobiology of Disease, 2013, 54, 486-491.	4.4	14
57	Diagnosis associated with Tau higher than 1200â€¯pg/mL: Insights from the clinical and laboratory practice. Clinica Chimica Acta, 2019, 495, 451-456.	1.1	13
58	Positive effects of lumbar puncture simulation training for medical students in clinical practice. BMC Medical Education, 2021, 21, 18.	2.4	13
59	Time Orientation and 10 Years Risk ofÂDementia in Elderly Adults: TheÂThree-City Study. Journal of Alzheimer's Disease, 2016, 53, 1411-1418.	2.6	12
60	Plasma neuregulin 1 as a synaptic biomarker in Alzheimerâ€™s disease: a discovery cohort study. Alzheimer's Research and Therapy, 2022, 14, .	6.2	12
61	The screening of Alzheimerâ€™s patients with CSF biomarkers, modulates the distribution of APOE genotype: impact on clinical trials. Journal of Neurology, 2014, 261, 1187-1195.	3.6	11
62	Dual Kinase Inhibition Affords Extended inÂvitro Neuroprotection in Amyloid-Î² Toxicity. Journal of Alzheimer's Disease, 2016, 54, 1659-1670.	2.6	11
63	Blood-Based Kinase Assessments in Alzheimerâ€™s Disease. Frontiers in Aging Neuroscience, 2018, 10, 338.	3.4	11
64	Pro-Apoptotic Kinase Levels in Cerebrospinal Fluid as Potential Future Biomarkers in Alzheimerâ€™s Disease. Frontiers in Neurology, 2015, 6, 168.	2.4	10
65	Brimapitide Reduced Neuronal Stress Markers and Cognitive Deficits in 5XFAD Transgenic Mice. Journal of Alzheimer's Disease, 2018, 63, 665-674.	2.6	10
66	Cerebrospinal Fluid Profile of Tau, Phosphorylated Tau, AÎ²42, and AÎ²40 in Probable Cerebral Amyloid Angiopathy. Journal of Alzheimer's Disease, 2022, 87, 791-802.	2.6	10
67	Increased Cerebrospinal Fluid Tau Levels in Logopenic Variant of Alzheimer's Disease. Journal of Alzheimer's Disease, 2014, 39, 611-616.	2.6	9
68	Distribution of Cerebrospinal Fluid Biomarker Profiles in Patients Explored forÂCognitive Disorders. Journal of Alzheimer's Disease, 2018, 64, 889-897.	2.6	9
69	Cerebrospinal Fluid and Plasma Biomarkers do not Differ in the Presenile and Late-Onset Behavioral Variants of Frontotemporal Dementia. Journal of Alzheimer's Disease, 2020, 74, 903-911.	2.6	9
70	Interest of biological biomarkers in the diagnostic approach of neurocognitive disorders in the elderly. Revue Neurologique, 2020, 176, 677-683.	1.5	9
71	High-sensitivity quantification of acetylcholine and choline in human cerebrospinal fluid with a validated LC-MS/MS method. Talanta, 2021, 224, 121881.	5.5	9
72	New highly sensitive rodent and human tests for soluble amyloid precursor protein alpha quantification: preclinical and clinical applications in Alzheimerâ€™s disease. BMC Neuroscience, 2012, 13, 84.	1.9	8

#	Article	IF	Citations
73	Can we rely only on ratios of cerebrospinal fluid biomarkers for AD biological diagnosis?. Alzheimer's and Dementia, 2015, 11, 1125-1126.	0.8	8
74	Frontotemporal dementia is the leading cause of â€œtrueâ€•Aâ^'/T+ profiles defined with AÎ²_{42/40} ratio. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2019, 11, 161-169.	2.4	8
75	Cerebrospinal Fluid Biomarkers in Patients With Alcohol Use Disorder and Persistent Cognitive Impairment. Alcoholism: Clinical and Experimental Research, 2021, 45, 561-565.	2.4	8
76	Full-length and C-terminal neurogranin in Alzheimerâ€™s disease cerebrospinal fluid analyzed by novel ultrasensitive immunoassays. Alzheimer's Research and Therapy, 2020, 12, 168.	6.2	7
77	Neurofilaments as Emerging Biomarkers of Neuroaxonal Damage to Differentiate Behavioral Frontotemporal Dementia from Primary Psychiatric Disorders: A Systematic Review. Diagnostics, 2021, 11, 754.	2.6	7
78	Using virtual reality in lumbar puncture training improves students learning experience. BMC Medical Education, 2022, 22, 244.	2.4	7
79	Clinical reporting following the quantification of cerebrospinal fluid biomarkers in Alzheimer's disease: An international overview. Alzheimer's and Dementia, 2021, 17, .	0.8	7
80	Dose-dependent neuroprotective effect of the JNK inhibitor Brimapitide in 5xFAD transgenic mice. Brain Research, 2020, 1727, 146587.	2.2	6
81	Effect of antiâ€cancer drugs on microglia in patientâ€derived breast cancer xenografted mouse models. Neuropathology, 2017, 37, 91-93.	1.2	4
82	Bright light therapy improved sleep disturbances in a patient with dementia with Lewy bodies. Psychogeriatrics, 2020, 20, 124-125.	1.2	4
83	STAT3 inhibition reverses neuroinflammation and AÎ² metabolism induced by systemic inflammation. Alzheimer's and Dementia, 2020, 16, e041019.	0.8	4
84	Quantification of the trans-synaptic partners neurexin-neuroligin in CSF of neurodegenerative diseases by parallel reaction monitoring mass spectrometry. EBioMedicine, 2022, 75, 103793.	6.1	4
85	Brain Glucose Metabolism in Cerebral Amyloid Angiopathy. Stroke, 2021, 52, 1478-1482.	2.0	3
86	Determinants of Post-Operative Cognitive Decline in Elderly People. journal of prevention of Alzheimer's disease, The, 2021, 8, 1-7.	2.7	3
87	Telemedicine in French Memory Clinics During the COVID-19 Pandemic. Journal of Alzheimer's Disease, 2022, 86, 525-530.	2.6	3
88	Biogenesis and regulation of microRNA: implication in Alzheimerâ€™s disease. Future Neurology, 2010, 5, 839-850.	0.5	2
89	O2â€05â€01: CEREBROSPINAL FLUID SYNAPTIC VESICLE GLYCOPROTEIN 2A IN ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2019, 15, P545.	0.8	2
90	Association of Amyotrophic Lateral Sclerosis and Alzheimerâ€™s Disease: New Entity or Coincidence? A Case Series. Journal of Alzheimer's Disease, 2021, 84, 1439-1446.	2.6	2

#	Article	IF	Citations
91	Could ryanodine receptor dysfunction be linked to PKR brain accumulations in Alzheimerâ€™s disease?. Medical Hypotheses, 2018, 113, 45.	1.5	1
92	Increased PKR level in human CADASIL brains. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2018, 473, 771-774.	2.8	1
93	The Diagnostic Value of a Short Memory Test: The TNI-93. Journal of Alzheimer's Disease, 2021, , 1-11.	2.6	1
94	Is there a link between headache and cognitive disorders? A systematic review. Revue Neurologique, 2022, 178, 285-290.	1.5	1
95	Biomarqueurs du liquide cÃ©rÃ©brospinal dans la maladie dâ€™Alzheimer. Bulletin De L'Academie Nationale De Medecine, 2018, 202, 307-320.	0.0	1
96	O3â€14â€06: DISSECTION OF SYNAPTIC PATHWAYS THROUGH THE ANALYSIS OF BIOMARKERS IN THE CSF: A COMBINING TOOL FOR THE DIAGNOSIS OF ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P1061.	0.8	0
97	P1â€092: NEUROPROTECTIVE EFFECTS OF PKR KNOCKOUT IN 5XFAD ALZHEIMER MICE AND NEURONâ€MICROGLIA COâ€CULTURES. Alzheimer's and Dementia, 2018, 14, P306.	0.8	0
98	P3â€249: COMBINING MATHEMATICAL MODEL AND CATECHOLAMINE QUANTIFICATIONS TO SCREEN ALZHEIMER DISEASE FROM A SIMPLE BLOOD TEST. Alzheimer's and Dementia, 2018, 14, P1168.	0.8	0
99	P2â€277: CORTICAL SULCI WIDTH AND INCIDENT DEMENTIA IN OUTPATIENTS ATTENDING FRENCH MEMORY CLINICS: THE MEMENTO COHORT. Alzheimer's and Dementia, 2018, 14, P784.	0.8	0
100	CSF levels of the BACE1 substrate Neuregulin1 correlate with cognition and synaptic biomarkers in Alzheimerâ€™s disease. Alzheimer's and Dementia, 2020, 16, e037097.	0.8	0
101	Inâ€vivo characterization of progressive amnestic syndrome due to suspected neurodegenerative nonâ€Alzheimerâ€™s disease. Alzheimer's and Dementia, 2020, 16, e039587.	0.8	0
102	Memory assessment in illiterate patients: The diagnostic value of the TNI 93. Alzheimer's and Dementia, 2020, 16, e042059.	0.8	0
103	Association of Alzheimer's disease and amyotrophic lateral sclerosis: A series of cases and review of the literature. Alzheimer's and Dementia, 2020, 16, e045814.	0.8	0
104	Bloodâ€based detection of earlyâ€stage Alzheimer using multiomics and machine learning. Alzheimer's and Dementia, 2020, 16, e047334.	0.8	0
105	Cerebrospinal fluid neurogranin in Alzheimerâ€™s disease studies: are immunoassay results interchangeable?. Clinical Chemistry and Laboratory Medicine, 2021, 60, e13-e17.	2.3	0
106	Diagnostic prÃ©coce et biomarqueurs biologiques de la maladie d'Alzheimer. NPG Neurologie - Psychiatrie - Geriatrie, 2020, 20, 120S7-120S10.	0.2	0
107	Alcohol misuse can mimic frontotemporal degeneration in Alzheimer's disease patients. Revue Neurologique, 2021, , .	1.5	0
108	Biomarqueurs de la maladie d'Alzheimer: des avancÃ©es trÃ¨s rapides. La Presse MÃ©dicale Formation, 2022, , .	0.1	0

#	Article	IF	Citations
109	Telemedicine in French memory clinics during Covidâ€19 crisis. Alzheimer's and Dementia, 2021, 17, e052037.	0.8	0
110	Longâ€term cognitive and motor decline across the spectrum of Lewy body disease. Alzheimer's and Dementia, 2021, 17, .	0.8	0
111	Plasma pâ€tau231 in the Alzheimerâ€™s disease continuum: A multiâ€cohort evaluation of diagnostic performance, detection of Aî² pathology and preclinical application. Alzheimer's and Dementia, 2021, 17, .	0.8	0
112	Title is missing!. , 2020, 17, e1003289.		0
113	Title is missing!. , 2020, 17, e1003289.		0
114	Title is missing!. , 2020, 17, e1003289.		0
115	Title is missing!. , 2020, 17, e1003289.		0
116	Title is missing!. , 2020, 17, e1003289.		0
117	Title is missing!. , 2020, 17, e1003289.		0
118	Title is missing!. , 2020, 17, e1003289.		0